CombiGene recently strengthened its gene therapy project CG01 in the best possible way when it signed an exclusive, global collaboration and licensing agreement with Spark Therapeutics worth over 320 MUSD. In 2022, the company’s final preparations for the first-in-human study, in collaboration with Spark, are a top priority. BioStock reached out to CombiGene´s CEO Jan Nilsson, to learn about his expectations.
https://www.biostock.se/en/2021/12/combigenes-ceo-about-the-path-to-the-first-clinical-trial/